COVID-19 Outpatient Study: Ridgeback Biotherapeutics, LP - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if the study medicine (EIDD-2801) can reduce the amount of virus in someone's body, improve symptoms, and reduce complications.
We are also looking at whether this medication will reduce the spread of the virus between people.
Who Can Participate in the Study?
Adults that have:
-Developed symptoms for COVID-19 within 7 days of signing up for this study
-Experienced at least 1 symptom of COVID-19
-Are not in the hospital
What is Involved?
If you choose to join this study, you will:
-Be randomized (like flipping a coin) to Group 1 or Group 2:
--Group 1 will take the study medicine (EIDD-2801) for 5 days
--Group 2 will take a placebo (inactive study pill that does nothing) for 5 days
Both groups will:
-Give blood samples
-Have nasal swabs
-Take the study medicine
-Have either in-clinic or at-home visits during the 2 weeks you are infected with COVID-19